Skip to main content
logo
Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
32.28
-1.49 (-4.41%)
At close: Mar 3, 2026, 4:00 PM EST
33.14
+0.86 (2.66%)
Pre-market: Mar 4, 2026, 7:25 AM EST

Teva Pharmaceutical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
17,25816,54415,84614,92515,878
Revenue Growth (YoY)
4.32%4.41%6.17%-6.00%-4.69%
Cost of Revenue
8,3208,4818,2007,9528,284
Gross Profit
8,9388,0647,6456,9737,594
Selling, General & Admin
3,9733,7023,4983,4453,528
Research & Development
1,013998953838967
Other Operating Expenses
1,7943,6662,7624,8871,384
Total Operating Expenses
6,7808,3667,2139,1705,879
Operating Income
2,157-303433-2,1971,716
Interest Expense
-934-981-1,057-966-1,058
Other Non-Operating Income (Expense)
-15-1-2-21-9
Total Non-Operating Income (Expense)
-949-982-1,059-987-1,067
Pretax Income
1,223-1,284-624-3,163658
Provision for Income Taxes
-180676-7-643211
Net Income
1,411-1,639-559-2,446417
Minority Interest in Earnings
7-320-56-5339
Net Income to Common
1,411-1,639-559-2,446417
Shares Outstanding (Basic)
1,1451,1311,1191,1101,102
Shares Outstanding (Diluted)
1,1631,1311,1191,1101,107
Shares Change (YoY)
2.83%1.07%0.81%0.27%1.10%
EPS (Basic)
1.23-1.45-0.50-2.200.38
EPS (Diluted)
1.21-1.45-0.50-2.200.38
Free Cash Flow
1,1487498421,042236
Free Cash Flow Growth
53.27%-11.04%-19.19%341.52%-63.01%
Free Cash Flow Per Share
0.990.660.750.940.21
Gross Margin
51.79%48.74%48.25%46.72%47.83%
Operating Margin
12.50%-1.83%2.73%-14.72%10.81%
Profit Margin
8.22%-11.84%-3.88%-16.74%2.87%
FCF Margin
6.65%4.53%5.31%6.98%1.49%
EBITDA
3,1597561,586-8893,046
EBITDA Margin
18.30%4.57%10.01%-5.96%19.18%
EBIT
2,157-303433-2,1971,716
EBIT Margin
12.50%-1.83%2.73%-14.72%10.81%
Effective Tax Rate
-14.72%-52.65%1.12%20.33%32.07%
Updated Jan 28, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q